Eliem Therapeutics, Inc. (ELYM)
ELYM has a market cap or net worth of $91.13 million. The enterprise value is -$45.35 million.
The next earnings date is Monday, June 6, 2022, before market open.
|Estimated Earnings Date||Jun 6, 2022|
ELYM has 26.57 million shares outstanding. The number of shares has increased by 460.40% in one year.
|Shares Change (YoY)||+460.40%|
|Shares Change (QoQ)||-21.33%|
|Owned by Insiders (%)||33.19%|
|Owned by Institutions (%)||72.45%|
|EV / Earnings||n/a|
|EV / Sales||n/a|
|EV / EBITDA||n/a|
|EV / EBIT||n/a|
|EV / FCF||n/a|
|Debt / Equity||0.00|
|Debt / EBITDA||0.00|
|Debt / FCF||0.00|
Return on equity (ROE) is -83.30%, which is considered low. The company has a ROIC of -79.70%.
|Return on Equity (ROE)||-83.30%|
|Return on Assets (ROA)||-40.30%|
|Return on Capital (ROIC)||-79.70%|
|Revenue Per Employee||n/a|
|Profits Per Employee||-$1.41M|
|Effective Tax Rate||n/a|
Stock Price Statistics
|Total Price Change||-72.56%|
|50-Day Moving Average||5.50|
|200-Day Moving Average||9.74|
|Average Volume (30 Days)||197,398|
Short Selling Information
The latest short interest is 1.05 million, so 3.94% of the outstanding shares have been sold short.
|Short % of Shares Out||3.94%|
|Short % of Float||47.39%|
|Short Ratio (days to cover)||3.91|
|Net Income Common||-52.03M|
|Earnings Per Share (EPS)||-$2.54|
The company has $136.48 million in cash and no debt, giving a net cash position of $136.48 million or $5.14 per share.
|Cash & Cash Equivalents||136.48M|
|Net Cash Per Share||$5.14|
|Book Value Per Share||6.29|
|Operating Cash Flow||-36.07M|
|Free Cash Flow||-36.07M|
|FCF Per Share||n/a|
Dividends & Yields
ELYM does not appear to pay any dividends at this time.
|Dividend Per Share||n/a|
|Dividend Growth (YoY)||n/a|
The average price target for ELYM is $24.48, which is 613.70% higher than the current price. The consensus rating is "Buy".
|Price Target Difference||613.70%|
This stock does not have any record of stock splits.
|Last Split Date||n/a|